BlueWillow Biologics
Dr. Chad Costley became the President and Chief Executive Officer of BlueWillow Biologics in 2020 after serving on the Board of Directors for several years. Dr. Costley has 20 years of clinical practice experience and has advised and served on the Boards of Directors of several technology companies. As the managing director of Waubascon Capital and Line Moon Ventures, he’s led investment in and supported BlueWillow’s advancement for many years. He earned his MD at the University of Michigan where he also completed medical residency training. He holds a MBA with distinction from Emory University as a Woodruff Scholar.
This person is not in any teams
This person is not in any offices
BlueWillow Biologics
BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow’s technology has been advanced significantly in recent years yielding several therapies in development.